Published in Cancer Weekly, April 14th, 2009
"However, unlike 2 and 3, compound 4 fails to down-regulate estrogen receptor alpha (ER alpha)," wrote V. Agouridas and colleagues, University of Versailles.
The researchers concluded: "This result suggests that ER alpha down-regulation is not a sine qua non condition for the antitumor activity of steroidal antiestrogens."
Agouridas and colleagues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.